These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32569231)

  • 1. A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments.
    Özdirik B; Tacke F; Benz F; Amthauer H; Fehrenbach U; Roderburg C; Jann H
    Medicine (Baltimore); 2020 Jun; 99(25):e20820. PubMed ID: 32569231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study.
    Mirvis E; Mandair D; Garcia-Hernandez J; Mohmaduvesh M; Toumpanakis C; Caplin M
    Anticancer Res; 2014 Nov; 34(11):6601-7. PubMed ID: 25368264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegylated interferon-α2b for local control of Langerhans cell sarcoma.
    Ishitsuka Y; Iwamoto K; Oya K; Nakamura Y; Watanabe R; Okiyama N; Fujisawa Y; Fujimoto M
    Eur J Dermatol; 2018 Dec; 28(6):835-836. PubMed ID: 30355544
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.
    Goldman S; Pollack IF; Jakacki RI; Billups CA; Poussaint TY; Adesina AM; Panigrahy A; Parsons DW; Broniscer A; Robinson GW; Robison NJ; Partap S; Kilburn LB; Onar-Thomas A; Dunkel IJ; Fouladi M
    Neuro Oncol; 2020 Nov; 22(11):1696-1704. PubMed ID: 32393959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.
    Wang KL; Xing HQ; Zhao H; Liu JW; Gao DL; Zhang XH; Yao HY; Yan L; Zhao J
    World J Gastroenterol; 2014 Apr; 20(14):4071-5. PubMed ID: 24744598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety and efficacy of conventional interferon versus pegylated-interferon based therapy for HCV: A retrospective cohort study from Gujranwala, Pakistan.
    Iftikhar U; Ahmed M; Saeed H; Saleem N; Bashir A; Farooq MS; Kamran SH; Saleem Z
    Pak J Pharm Sci; 2020 Sep; 33(5):2037-2045. PubMed ID: 33824111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
    Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
    Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report.
    Maunsell R; Bellomo-Brandão MA
    Sao Paulo Med J; 2018; 136(4):376-381. PubMed ID: 28977096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
    Sun J; Ding H; Chen G; Wang G; Wei L; Zhang J; Xie Q; Wan M; Tang H; Chen S; Gao Z; Wang Y; Zhang D; Huang W; Sheng J; Ning Q; Yang D; Lu J; Pan C; Yang Y; Wang J; Sun C; Wang Q; Hou J
    BMC Gastroenterol; 2019 May; 19(1):65. PubMed ID: 31046700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
    Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
    J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.